As an adjunct to our studies on the effects of insulin in pancreatic cancer cells, we compared native insulin to a short-acting insulin analogue (LisproTM) and a long-acting insulin analogue (GlargineTM) on the viability of PANC1 cells. This evidence concerns the gene INS and pancreatic neoplasm.